Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $24.00 at JonesTrading

Trevi Therapeutics (NASDAQ:TRVI) had its price objective decreased by JonesTrading from $25.00 to $24.00 in a research report released on Thursday morning,Benzinga reports. JonesTrading currently has a buy rating on the stock.

A number of other analysts have also commented on TRVI. Leerink Partners upped their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Monday, March 9th. D. Boral Capital restated a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Wednesday. Stifel Nicolaus upped their price target on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and an average target price of $21.60.

Trevi Therapeutics Stock Up 0.1%

Shares of Trevi Therapeutics stock opened at $10.70 on Thursday. The stock’s fifty day moving average is $11.14 and its 200-day moving average is $10.93. The firm has a market capitalization of $1.37 billion, a PE ratio of -33.44 and a beta of 0.94. Trevi Therapeutics has a 12-month low of $4.85 and a 12-month high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. Analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its holdings in shares of Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares during the period. Hilton Head Capital Partners LLC purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Trevi Therapeutics during the fourth quarter worth approximately $50,000. Strs Ohio acquired a new stake in shares of Trevi Therapeutics during the first quarter worth approximately $52,000. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Trevi Therapeutics during the second quarter valued at approximately $56,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

More Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Company says it achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and regulatory de‑risking milestone that can drive long‑term value if trials and endpoints are favorable. Article Title
• Positive Sentiment: Q4 2025 results topped expectations — EPS of ($0.06) vs. consensus ~($0.0966). The beat and management commentary from the earnings call support near‑term credibility on execution. Earnings Transcript
• Positive Sentiment: Broker support remains strong: Needham raised its target to $24 (Buy) and HC Wainwright reiterated a Buy with a $21 target and updated EPS forecasts — analyst backing increases visibility for upside expectations. Broker Note HC Wainwright Details
• Positive Sentiment: D. Boral Capital reaffirmed a Buy and $19 target, adding to the cluster of buy ratings—positive for investor sentiment and analyst coverage breadth. Article Title
• Neutral Sentiment: Morgan Stanley lowered its price target from $19 to $18 but kept an Overweight rating — still positive sentimentually, but the cut trims some near‑term upside expectations. Article Title
• Negative Sentiment: JonesTrading trimmed its target from $25 to $24 (remains a Buy) — a modest downward adjustment in analyst upside that slightly cools the market’s price‑target momentum. Article Title

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.